{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:23:56Z","timestamp":1787027036251,"version":"build-2736575974"},"reference-count":108,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T00:00:00Z","timestamp":1632096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    As a third-generation antiseizure medication (ASM), lacosamide (LCM) is recommended worldwide for patients with epilepsy. We aimed to provide more conclusive evidence for the safety and tolerability of LCM in patients with epilepsy.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    A systematic search was performed on MEDLINE, Embase, Cochrane Library, CBM, CNKI, IDB, VIP Database, and Wanfang Database from inception to 2021 March, and all studies assessing the safety of LCM were included. A meta-analysis was performed for safety data of LCM.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    Eighty-three studies involving 12268 populations (11 randomized clinical trials (RCTs), 16 cohort studies, 53 case series, and 3 case reports) were included in our study. Meta-analysis of the total incidence of adverse events (AEs) of LCM was 38.7% [95% CI (35.1%, 45.8%);\n                    <jats:italic>n<\/jats:italic>\n                    =75 studies]. Incidence of withdrawal due to AEs was 10.8% [95% CI (9.1%, 12.6%);\n                    <jats:italic>n<\/jats:italic>\n                    =56 studies], and incidence of serious adverse events (SAEs) was 6.5% [95% CI (4.0%, 8.9%);\n                    <jats:italic>n<\/jats:italic>\n                    =13 studies]. Most AEs were in the nervous system and digestive system. The most common AEs were sedation (15.8%), dizziness (15.7%), fatigue (9.4%), and nausea\/vomiting (9.3%). For children, the total incidence of AEs of LCM was 32.8% [95% CI (21.6%, 44.0%);\n                    <jats:italic>n<\/jats:italic>\n                    =16 studies], and the most common AEs were dizziness (8.6%), nausea\/vomiting (8.6%), and somnolence (6.8%).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    Lacosamide is generally safe and well tolerated in patients with epilepsy. Common AEs were sedation, dizziness, and fatigue. It is necessary to pay more attention to the prevention and management of these AEs and conduct more large-scale and high-quality studies to update safety data.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2021.694381","type":"journal-article","created":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T00:25:51Z","timestamp":1632097551000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":26,"title":["Safety and Tolerability of Lacosamide in Patients With Epilepsy: A Systematic Review and Meta-Analysis"],"prefix":"10.3389","volume":"12","author":[{"given":"Chunsong","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxuan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,9,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.seizure.2015.10.009","article-title":"Efficacy and Tolerability of Add-On Lacosamide Treatment in Adults with Lennox-Gastaut Syndrome: An Observational Study","volume":"33","author":"Andrade-Machado","year":"2015","journal-title":"Seizure"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1007\/s12098-014-1533-1","article-title":"Refractory Epilepsy in Children","volume":"81","author":"Aneja","year":"2014","journal-title":"Indian J. Pediatr."},{"key":"B3","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.yebeh.2018.04.020","article-title":"Efficacy and Tolerability of Treatment with Lacosamide: Postmarketing Experience from the Middle East Region","volume":"84","author":"Arabi","year":"2018","journal-title":"Epilepsy Behav."},{"key":"B4","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.ejpn.2015.12.013","article-title":"Clinical Experience of Intravenous Lacosamide in Infants and Young Children","volume":"20","author":"Arkilo","year":"2016","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.clineuro.2018.06.022","article-title":"Lacosamide Efficacy and Tolerability in Clinical Practice - Post Marketing Analysis from a Single Dedicated Epilepsy center","volume":"171","author":"Baker","year":"2018","journal-title":"Clin. Neurol. Neurosurg."},{"key":"B6","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1684\/epd.2017.0907","article-title":"Adjunctive Lacosamide for Focal Epilepsy: an Open-Label Trial Evaluating the Impact of Flexible Titration and Dosing on Safety and Seizure Outcomes","volume":"19","author":"Baulac","year":"2017","journal-title":"Epileptic Disord."},{"key":"B7","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1111\/epi.12605","article-title":"An Unknown Quantity-Tthe Worldwide Prevalence of Epilepsy","volume":"55","author":"Bell","year":"2014","journal-title":"Epilepsia"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1111\/j.1528-1167.2007.01188.x","article-title":"Efficacy and Safety of Oral Lacosamide as Adjunctive Therapy in Adults with Partial-Onset Seizures","volume":"48","author":"Ben-Menachem","year":"2007","journal-title":"Epilepsia"},{"key":"B9","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.yebeh.2015.09.006","article-title":"Safety and Tolerability of Lacosamide as Adjunctive Therapy for Adults with Partial-Onset Seizures: Analysis of Data Pooled from Three Randomized, Double-Blind, Placebo-Controlled Clinical Trials","volume":"52","author":"Biton","year":"2015","journal-title":"Epilepsy Behav."},{"key":"B10","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s13760-020-01488-y","article-title":"Recommendations for the Treatment of Epilepsy in Adult and Pediatric Patients in Belgium: 2020 Update","volume":"121","author":"Boon","year":"2021","journal-title":"Acta Neurol. Belg."},{"key":"B11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.yebeh.2016.03.011","article-title":"Lacosamide in Patients with Temporal Lobe Epilepsy: An Observational Multicentric Open-Label Study","author":"Borz\u00ec","year":"2016","journal-title":"Epilepsy Behav."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1111\/epi.13869","article-title":"Lacosamide in the Treatment of Patients with Epilepsy and Intellectual Disabilities: A Long-Term Study of 136 Patients","volume":"58","author":"B\u00f6ttcher","year":"2017","journal-title":"Epilepsia"},{"key":"B13","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.seizure.2017.09.017","article-title":"The Retention of Lacosamide in Patients with Epilepsy and Intellectual Disability in Three Specialised Institutions","volume":"52","author":"Brenner","year":"2017","journal-title":"Seizure"},{"key":"B14","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.yebeh.2013.11.016","article-title":"Prospective Audits with Newer Antiepileptic Drugs in Focal Epilepsy: Insights into Population Responses?","volume":"31","author":"Brodie","year":"2014","journal-title":"Epilepsy Behav."},{"key":"B15","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1111\/bcp.12176","article-title":"Meta-analyses of Antiepileptic Drugs for Refractory Partial (Focal) Epilepsy: an Observation","volume":"76","author":"Brodie","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2165\/11636260-000000000-00000","article-title":"Efficacy and Tolerability of Lacosamide in the Concomitant Treatment of 130 Patients under 16 Years of Age with Refractory Epilepsy","volume":"12","author":"Casas-Fern\u00e1ndez","year":"2012","journal-title":"Drugs R. D"},{"key":"B17","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.yebeh.2019.02.022","article-title":"Long-term Efficacy and Safety of Lacosamide and Levetiracetam Monotherapy in Elderly Patients with Focal Epilepsy: A Retrospective Study[J]","volume":"94","author":"Chiara Del","year":"2019","journal-title":"Epilepsy Behav."},{"key":"B18","doi-asserted-by":"publisher","first-page":"107449","DOI":"10.1016\/j.yebeh.2020.107449","article-title":"Safety, Tolerability, and Pharmacokinetics of Weight-Based IV Loading Dose of Lacosamide in the ICU","volume":"114","author":"Chimakurthy","year":"2020","journal-title":"Epilepsy Behav."},{"key":"B19","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1111\/j.1528-1167.2009.02496.x","article-title":"Lacosamide as Adjunctive Therapy for Partial-Onset Seizures: a Randomized Controlled Trial","volume":"51","author":"Chung","year":"2010","journal-title":"Epilepsia"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.2147\/TCRM.S171793","article-title":"Adjunctive Lacosamide Treatment for Adult Focal-Onset Epilepsy: Focus on Comorbid Intellectual\/developmental Disorders and Differing Responses","volume":"14","author":"Do\u011fan","year":"2018","journal-title":"Ther. Clin. Risk Manag."},{"key":"B22","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.seizure.2019.05.016","article-title":"Safety and Tolerability of Adjunctive Lacosamide in a Pediatric Population with Focal Seizures - an Open-Label Trial","volume":"71","author":"Ferreira","year":"2019","journal-title":"Seizure"},{"key":"B24","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.seizure.2012.05.005","article-title":"Clinical Experience with Oral Lacosamide as Adjunctive Therapy in Adult Patients with Uncontrolled Epilepsy: a Multicentre Study in Epilepsy Clinics in the United Kingdom (UK)","volume":"21","author":"Flores","year":"2012","journal-title":"Seizure"},{"key":"B25","doi-asserted-by":"publisher","first-page":"74","DOI":"10.12809\/hkmj166027","article-title":"An Update of the Hong Kong Epilepsy Guideline: Consensus Statement on the Use of Antiepileptic Drugs in Hong Kong","volume":"23","author":"Fong","year":"2017","journal-title":"Hong Kong Med. J."},{"key":"B26","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/j.1528-1167.2012.03543.x","article-title":"Safety and Tolerability of Adjunctive Lacosamide Intravenous Loading Dose in Lacosamide-Naive Patients with Partial-Onset Seizures","volume":"54","author":"Fountain","year":"2013","journal-title":"Epilepsia"},{"key":"B27","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jclinepi.2013.08.003","article-title":"The CARE Guidelines: Consensus-Based Clinical Case Report Guideline Development","volume":"67","author":"Gagnier","year":"2014","journal-title":"J. Clin. Epidemiol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.yebeh.2014.05.015","article-title":"Factors Influencing Response to Intravenous Lacosamide in Emergency Situations: LACO-IV Study","volume":"36","author":"Garc\u00e9s","year":"2014","journal-title":"Epilepsy Behav."},{"key":"B29","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.seizure.2011.08.005","article-title":"Early Clinical Experience with Lacosamide as Adjunctive Therapy in Patients with Refractory Focal Epilepsy and Nocturnal Seizures","volume":"20","author":"Garc\u00eda-Morales","year":"2011","journal-title":"Seizure: Eur. J. Epilepsy"},{"key":"B30","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.yebeh.2011.02.005","article-title":"Efficacy and Tolerability of Oral Lacosamide as Adjunctive Therapy in Pediatric Patients with Pharmacoresistant Focal Epilepsy","volume":"20","author":"Gavatha","year":"2011","journal-title":"Epilepsy Behav."},{"key":"B31","doi-asserted-by":"publisher","first-page":"S673","DOI":"10.1016\/j.ijrobp.2011.06.929","article-title":"Common Terminology Criteria for Adverse Events (CTCAE) v4.0 Based Hybrid Patient and Physician Questionnaire for Head and Neck (HN) Radiotherapy Symptom Reporting","volume":"81","author":"Gay","year":"2011","journal-title":"Int. J. Radiat. Oncology*Biology*Physics"},{"key":"B32","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.eplepsyres.2015.02.008","article-title":"Lacosamide Use in the Treatment of Refractory Epilepsy in Tuberous Sclerosis Complex","volume":"112","author":"Geffrey","year":"2015","journal-title":"Epilepsy Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"593149","DOI":"10.1155\/2013\/593149","article-title":"A Clinical-EEG Study of Sleepiness and Psychological Symptoms in Pharmacoresistant Epilepsy Patients Treated with Lacosamide","volume":"2013","author":"Giorgi","year":"2013","journal-title":"Epilepsy Res. Treat."},{"key":"B34","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.seizure.2015.04.003","article-title":"Long-term Efficacy and Safety of Lacosamide Monotherapy in the Treatment of Partial-Onset Seizures: A Multicenter Evaluation","volume":"29","author":"Gir\u00e1ldez","year":"2015","journal-title":"Seizure: Eur. J. Epilepsy"},{"key":"B35","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.ejpn.2014.04.013","article-title":"Lacosamide in Children with Refractory Status Epilepticus. A Multicenter Italian Experience","volume":"18","author":"Grosso","year":"2014","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.pediatrneurol.2010.12.003","article-title":"Experience with Lacosamide in a Series of Children with Drug-Resistant Focal Epilepsy","volume":"44","author":"Guilhoto","year":"2010","journal-title":"Pediatr. Neurol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/j.1528-1167.2008.01951.x","article-title":"Adjunctive Lacosamide for Partial-Onset Seizures: Efficacy and Safety Results from a Randomized Controlled Trial","volume":"50","author":"Hal\u00e1sz","year":"2009","journal-title":"Epilepsia"},{"key":"B38","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.eplepsyres.2011.09.010","article-title":"Initial post Marketing Experience with Lacosamide in Adult Patients with Epilepsy","volume":"98","author":"Harden","year":"2012","journal-title":"Epilepsy Res."},{"key":"B39","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ejpn.2011.08.007","article-title":"Preliminary Efficacy and Safety of Lacosamide in Children with Refractory Epilepsy","volume":"16","author":"Heyman","year":"2012","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"B40","doi-asserted-by":"crossref","DOI":"10.1002\/9781119536604","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.0[Z]","author":"Higgins","year":"2019"},{"key":"B41","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.seizure.2020.04.016","article-title":"Efficacy and Tolerability of Treatment with Lacosamide in Children: Postmarketing Experience from the Middle East","volume":"79","author":"Hmaimess","year":"2020","journal-title":"Seizure"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e148","DOI":"10.1111\/j.1528-1167.2011.03204.x","article-title":"Intravenous Lacosamide in Status Epilepticus and Seizure Clusters","volume":"52","author":"H\u00f6fler","year":"2011","journal-title":"Epilepsia"},{"key":"B43","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.eplepsyres.2016.08.032","article-title":"Efficacy and Safety of Adjunctive Lacosamide for the Treatment of Partial-Onset Seizures in Chinese and Japanese Adults: A Randomized, Double-Blind, Placebo-Controlled Study","volume":"127","author":"Hong","year":"2016","journal-title":"Epilepsy Res."},{"key":"B44","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1097\/WNP.0000000000000479","article-title":"Electroencephalographic and Electrocardiographic Effect of Intravenous Lacosamide in Refractory Focal Epilepsy","volume":"35","author":"Huang","year":"2018","journal-title":"J. Clin. Neurophysiol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1111\/j.1528-1167.2012.03407.x","article-title":"Long-term Safety and Efficacy in Patients with Uncontrolled Partial-Onset Seizures Treated with Adjunctive Lacosamide: Results from a Phase III Open-Label Extension Trial","volume":"53","author":"Husain","year":"2012","journal-title":"Epilepsia"},{"key":"B46","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/ane.12372","article-title":"Cognitive Effects of Lacosamide as Adjunctive Therapy in Refractory Epilepsy","volume":"131","author":"IJff","year":"2015","journal-title":"Acta Neurol. Scand."},{"key":"B47","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/j.1600-0404.2012.01704.x","article-title":"Clinical Experience with Using Lacosamide for the Treatment of Epilepsy in a Tertiary centre","volume":"127","author":"Kamel","year":"2013","journal-title":"Acta Neurol. Scand."},{"key":"B49","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/ane.12174","article-title":"Intravenous Lacosamide or Phenytoin for Treatment of Refractory Status Epilepticus","volume":"129","author":"Kellinghaus","year":"2014","journal-title":"Acta Neurol. Scand."},{"key":"B50","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.braindev.2013.07.003","article-title":"Lacosamide as an Adjunctive Therapy in Pediatric Patients with Refractory Focal Epilepsy","volume":"36","author":"Kim","year":"2014","journal-title":"Brain Dev."},{"key":"B51","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s13760-019-01098-3","article-title":"Lacosamide in Patients with Intellectual Disability and Refractory Epilepsy","volume":"119","author":"Kleist","year":"2019","journal-title":"Acta Neurol. Belg."},{"key":"B52","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.reprotox.2020.04.043","article-title":"Lacosamide Levels in Blood and Breastmilk during Pregnancy and Lactation: A Case Report","volume":"97","author":"Kohn","year":"2020","journal-title":"Reprod. Toxicol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.yebeh.2011.02.006","article-title":"Atrioventricular Block Following Lacosamide Intoxication","volume":"20","author":"Krause","year":"2011","journal-title":"Epilepsy Behav."},{"key":"B54","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.seizure.2016.11.012","article-title":"Clinical Outcomes of Perampanel vs. Lacosamide in Cohorts of Consecutive Patients with Severely Refractory Epilepsies - A Monocentric Retrospective Analysis of Systematically Collected Data from the German Kork Epilepsy Center","volume":"45","author":"Kurth","year":"2017","journal-title":"Seizure"},{"key":"B55","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1684\/epd.2021.1273","article-title":"Pharmacokinetic Data on Brivaracetam, Lacosamide and Perampanel during Pregnancy and Lactation","volume":"23","author":"Landmark","year":"2021","journal-title":"Epileptic Disord. : Int. epilepsy J. videotape"},{"key":"B56","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.pjnns.2017.03.003","article-title":"Lacosamide during Pregnancy and Breastfeeding","volume":"51","author":"Lattanzi","year":"2017","journal-title":"Neurol. Neurochir Pol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.seizure.2015.03.003","article-title":"Lacosamide Monotherapy for Partial Onset Seizures","volume":"27","author":"Lattanzi","year":"2015","journal-title":"Seizure"},{"key":"B58","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1111\/epi.16366","article-title":"Antiepileptic Drug Monotherapy for Epilepsy in the Elderly: A Systematic Review and Network Meta-Analysis","volume":"60","author":"Lattanzi","year":"","journal-title":"Epilepsia"},{"key":"B59","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/ane.13025","article-title":"Antiepileptic Monotherapy in Newly Diagnosed Focal Epilepsy. A Network Meta-Analysis","volume":"139","author":"Lattanzi","year":"","journal-title":"Acta Neurol. Scand."},{"key":"B60","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1080\/14740338.2020.1713089","article-title":"The Adverse-Effect Profile of Lacosamide","volume":"19","author":"Li","year":"2020","journal-title":"Expert Opin. Drug Saf."},{"key":"B61","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/j.1528-1167.2012.03651.x","article-title":"Rapid Loading of Intravenous Lacosamide: Efficacy and Practicability during Presurgical Video-EEG Monitoring","volume":"54","author":"Li","year":"2013","journal-title":"Epilepsia"},{"key":"B62","doi-asserted-by":"publisher","first-page":"3687","DOI":"10.3892\/etm.2020.9126","article-title":"Effects of Levetiracetam and Lacosamide on Therapeutic Efficacy and Neural Function in Patients with Epilepsy","volume":"20","author":"Liu","year":"2020","journal-title":"Exp. Ther. Med."},{"key":"B64","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.eplepsyres.2018.03.006","article-title":"Real World Experience with Lacosamide Monotherapy- a Single center 1-year Follow-Up Study","volume":"142","author":"Maloney","year":"2018","journal-title":"Epilepsy Res."},{"key":"B113","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.reprotox.2019.05.039","article-title":"Lacosamide use during pregnancy: An evaluation of the German embryotox database","volume":"88","author":"Maria","year":"2019","journal-title":"Reproduct. Toxicol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1007\/s00415-011-6132-8","article-title":"Lacosamide as Add-On in Brain Tumor-Related Epilepsy: Preliminary Report on Efficacy and Tolerability","volume":"258","author":"Maschio","year":"2011","journal-title":"J. Neurol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1111\/epi.13466","article-title":"Lacosamide Use in Children with Epilepsy: Retention Rate and Effect of Concomitant Sodium Channel Blockers in a Large Cohort","volume":"57","author":"McGinnis","year":"2016","journal-title":"Epilepsia"},{"key":"B67","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1177\/0883073816630084","article-title":"Efficacy and Tolerability of Lacosamide in the Treatment of Children with Refractory Generalized Epilepsy","volume":"31","author":"Miskin","year":"2016","journal-title":"J. Child. Neurol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/S0140-6736(14)60456-6","article-title":"Epilepsy: New Advances","volume":"385","author":"Mosh\u00e9","year":"2015","journal-title":"Lancet"},{"key":"B69","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.eplepsyres.2018.05.011","article-title":"LACONORTE Study: Efficacy and Security of Lacosamide as First Add-On Therapy for Focal-Onset Epilepsy in Real-Life Setting","volume":"145","author":"Mu\u00f1oz-Lopetegi","year":"2018","journal-title":"Epilepsy Res."},{"key":"B70","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.yebeh.2017.11.027","article-title":"Efficacy and Tolerability of Adjuvant Lacosamide: The Role of Clinical Characteristics and Mechanisms of Action of Concomitant AEDs","volume":"80","author":"Neal","year":"2018","journal-title":"Epilepsy Behav."},{"key":"B71","doi-asserted-by":"publisher","first-page":"8432859","DOI":"10.1155\/2018\/8432859","article-title":"Effectiveness and Adverse Effect of Intravenous Lacosamide in Nonconvulsive Status Epilepticus and Acute Repetitive Seizures in Children","volume":"2018","author":"Ngampoopun","year":"2018","journal-title":"Neurol. Res. Int."},{"key":"B72","unstructured":"Appendix 4 Quality of Case Series Form2002"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.seizure.2014.11.007","article-title":"Lacosamide as Adjunctive Therapy in Refractory Epilepsy in Adults: a Systematic Review","volume":"25","author":"Paquette","year":"2015","journal-title":"Seizure"},{"key":"B75","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.yebeh.2017.07.045","article-title":"Clinical Management of Elderly Patients with Epilepsy; the Use of Lacosamide in a Single center Setting","volume":"75","author":"Rainesalo","year":"2017","journal-title":"Epilepsy Behav."},{"key":"B76","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/j.1528-1167.2010.02915.x","article-title":"Factors Determining Response to Antiepileptic Drugs in Randomized Controlled Trials. A Systematic Review and Meta-Analysis","volume":"52","author":"Rheims","year":"2011","journal-title":"Epilepsia"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1111\/epi.14071","article-title":"Long-term Efficacy of Add-On Lacosamide Treatment in Children and Adolescents with Refractory Epilepsies: A Single-center Observational Study","volume":"59","author":"Rosati","year":"2018","journal-title":"Epilepsia"},{"key":"B78","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.yebeh.2014.09.074","article-title":"Safety and Efficacy of Adjunctive Lacosamide Among Patients with Partial-Onset Seizures in a Long-Term Open-Label Extension Trial of up to 8 Years","volume":"41","author":"Rosenfeld","year":"2014","journal-title":"Epilepsy Behav."},{"key":"B79","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1111\/epi.16486","article-title":"Effectiveness and Tolerability of Lacosamide as Add-On Therapy in Patients with Brain Tumor-Related Epilepsy: Results from a Prospective, Noninterventional Study in European Clinical Practice (VIBES)","volume":"61","author":"Rud\u00e0","year":"2020","journal-title":"Epilepsia"},{"key":"B80","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s11060-017-2628-0","article-title":"Lacosamide in Patients with Gliomas and Uncontrolled Seizures: Results from an Observational Study","volume":"136","author":"Rud\u00e0","year":"2018","journal-title":"J. Neurooncol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/jpc.14156","article-title":"Lacosamide in Children with Drug-Resistant Epilepsy","volume":"55","author":"R\u00fcegger","year":"2019","journal-title":"J. Paediatr. Child. Health"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1111\/epi.13224","article-title":"A Noninterventional Study Evaluating the Effectiveness and Safety of Lacosamide Added to Monotherapy in Patients with Epilepsy with Partial-Onset Seizures in Daily Clinical Practice: The VITOBA Study","volume":"56","author":"Runge","year":"2015","journal-title":"Epilepsia"},{"key":"B83","doi-asserted-by":"publisher","first-page":"e12669","DOI":"10.1111\/jsr.12669","article-title":"A Case Series of Lacosamide as Adjunctive Therapy in Refractory Sleep-Related Hypermotor Epilepsy (Previously Nocturnal Frontal Lobe Epilepsy)","volume":"27","author":"Samarasekera","year":"2018","journal-title":"J. Sleep Res."},{"key":"B84","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.yebeh.2017.11.024","article-title":"The Effectiveness and Safety of Lacosamide in Children with Epilepsy in a Clinical Practice Setting","volume":"79","author":"Sanmart\u00ed-Vilaplana","year":"2018","journal-title":"Epilepsy Behav."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.seizure.2017.04.010","article-title":"Tolerability of Lacosamide or Zonisamide in Elderly Patients with Seizures","volume":"49","author":"Sarkis","year":"2017","journal-title":"Seizure"},{"key":"B86","doi-asserted-by":"publisher","first-page":"106220","DOI":"10.1016\/j.eplepsyres.2019.106220","article-title":"Tolerability and Efficacy of Lacosamide and Controlled-Release Carbamazepine Monotherapy in Patients with Newly Diagnosed Epilepsy and Concomitant Psychiatric Conditions: Post Hoc Analysis of a Prospective, Randomized, Double-Blind Trial","volume":"159","author":"Schmitz","year":"2020","journal-title":"Epilepsy Res."},{"key":"B87","doi-asserted-by":"publisher","first-page":"4093","DOI":"10.3892\/ol.2017.5988","article-title":"Efficacy and Tolerability of Lacosamide for Secondary Epileptic Seizures in Patients with Brain Tumor: A Multicenter, Observational Retrospective Study","volume":"13","author":"Sep\u00falveda-S\u00e1nchez","year":"2017","journal-title":"Oncol. Lett."},{"key":"B88","doi-asserted-by":"publisher","first-page":"107663","DOI":"10.1016\/j.yebeh.2020.107663","article-title":"Tolerability of Lacosamide Rapid Dose Titration: A Randomized, Multicenter, Prospective, Open-Label Study","volume":"115","author":"Shin","year":"2021","journal-title":"Epilepsy Behav."},{"key":"B89","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s40278-020-81505-8","article-title":"Lacosamide","volume":"1815","author":"Stamm","year":"2020","journal-title":"React. Weekly"},{"key":"B90","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical Evaluation of the Newcastle-Ottawa Scale for the Assessment of the Quality of Nonrandomized Studies in Meta-Analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur. J. Epidemiol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2165\/11584860-000000000-00000","article-title":"Pharmacotherapy of Epilepsy: Newly Approved and Developmental Agents","volume":"25","author":"Stephen","year":"2011","journal-title":"CNS drugs"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/j.eplepsyres.2014.06.018","article-title":"Adjunctive Lacosamide--5 Years' Clinical Experience","volume":"108","author":"Stephen","year":"2014","journal-title":"Epilepsy Res."},{"key":"B93","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1111\/epi.13716","article-title":"Lacosamide in Status Epilepticus: Systematic Review of Current Evidence","volume":"58","author":"Strzelczyk","year":"2017","journal-title":"Epilepsia"},{"key":"B114","first-page":"94","article-title":"Clinical effect of lacoamide on childhood epilepsy","volume":"21","author":"Song","year":"2012","journal-title":"Chin. J. Aesth. Med."},{"key":"B94","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1007\/s11064-017-2234-8","article-title":"Therapeutic Drug Monitoring of Lacosamide in Norway: Focus on Pharmacokinetic Variability, Efficacy and Tolerability","volume":"42","author":"Svendsen","year":"2017","journal-title":"Neurochem. Res."},{"key":"B95","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/ane.12809","article-title":"Outcome of Cancer-Related Seizures in Patients Treated with Lacosamide","volume":"137","author":"Toledo","year":"2018","journal-title":"Acta Neurol. Scand."},{"key":"B96","volume-title":"U.S. National Library of Medicine","year":"2020"},{"key":"B97","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.seizure.2012.12.009","article-title":"Lacosamide in Pediatric and Adult Patients: Comparison of Efficacy and Safety","volume":"22","author":"Verrotti","year":"2013","journal-title":"Seizure"},{"key":"B98","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s40261-014-0255-5","article-title":"Early Add-On Lacosamide in a Real-Life Setting: Results of the REALLY Study","volume":"35","author":"Villanueva","year":"2015","journal-title":"Clin. Drug Investig."},{"key":"B99","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/ane.12920","article-title":"Lacosamide Monotherapy in Clinical Practice: A Retrospective Chart Review","volume":"138","author":"Villanueva","year":"2018","journal-title":"Acta Neurol. Scand."},{"key":"B100","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.yebeh.2013.07.024","article-title":"Control of Seizures in Different Stages of Partial Epilepsy: LACO-EXP, a Spanish Retrospective Study of Lacosamide","volume":"29","author":"Villanueva","year":"2013","journal-title":"Epilepsy Behav."},{"key":"B101","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.yebeh.2011.11.026","article-title":"Rational Polytherapy with Lacosamide in Clinical Practice: Results of a Spanish Cohort Analysis RELACOVA","volume":"23","author":"Villanueva","year":"2012","journal-title":"Epilepsy Behav."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1136\/jnnp-2020-323524","article-title":"Efficacy and Safety of Adjunctive Lacosamide in the Treatment of Primary Generalised Tonic-Clonic Seizures: a Double-Blind, Randomised, Placebo-Controlled Trial","volume":"91","author":"Vossler","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B103","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1111\/epi.13502","article-title":"Long-term Exposure and Safety of Lacosamide Monotherapy for the Treatment of Partial-Onset (Focal) Seizures: Results from a Multicenter, Open-Label Trial","volume":"57","author":"Vossler","year":"2016","journal-title":"Epilepsia"},{"key":"B104","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1111\/epi.12681","article-title":"Conversion to Lacosamide Monotherapy in the Treatment of Focal Epilepsy: Results from a Historical-Controlled, Multicenter, Double-Blind Study","volume":"55","author":"Wechsler","year":"2014","journal-title":"Epilepsia"},{"key":"B105","doi-asserted-by":"publisher","first-page":"CD008841","DOI":"10.1002\/14651858.CD008841.pub2","article-title":"Lacosamide Add-On Therapy for Partial Epilepsy","volume":"16","author":"Weston","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"B106","first-page":"824","article-title":"Safety and Efficacy of Lacosamide Tablets in the Treatment of Partial Epileptic Seizures","volume-title":"Proceedings of the 18th National Neurology Conference of Chinese Medical Association (II)","author":"Wu","year":"2015"},{"key":"B107","volume-title":"Clinical Observation of Lacosamide in the Treatment of Childhood Epilepsy and its Effect on Plasma Inflammatory Factor Levels [D]","author":"Yang","year":"2015"},{"key":"B109","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1177\/0883073812462887","article-title":"Efficacy of Lacosamide as Adjunctive Therapy in Children with Refractory Epilepsy","volume":"29","author":"Yorns","year":"2014","journal-title":"J. Child. Neurol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/j.1528-1167.2012.03589.x","article-title":"The Adverse Event Profile of Lacosamide: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"54","author":"Zaccara","year":"2013","journal-title":"Epilepsia"},{"key":"B111","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.seizure.2015.07.001","article-title":"Efficacy and Safety of Lacosamide as First Add-On or Later Adjunctive Treatment for Uncontrolled Partial-Onset Seizures: A Multicentre Open-Label Trial","volume":"31","author":"Zadeh","year":"2015","journal-title":"Seizure"},{"key":"B112","doi-asserted-by":"publisher","first-page":"107814","DOI":"10.1016\/j.yebeh.2021.107814","article-title":"Safety, Efficacy, and Tolerability of Lacosamide for the Treatment of Epilepsy in Pediatric Patients in Uygur, China","volume":"117","author":"Zhao","year":"2021","journal-title":"Epilepsy Behav."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.694381\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T00:26:01Z","timestamp":1632097561000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.694381\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,20]]},"references-count":108,"alternative-id":["10.3389\/fphar.2021.694381"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.694381","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,20]]},"article-number":"694381"}}